Danaher raises FY26 guidance on strong Q2 earnings
Danaher Corporation reported Q2 2026 net earnings of $870 million and revenue of $6.3 billion, a 5.5% increase. The company raised its full-year adjusted EPS guidance to $8.45–$8.60, driven by strong execution and the early close of the Masimo acquisition.
*this image is generated using AI for illustrative purposes only.
Danaher Corporation reported second quarter 2026 net earnings of $870 million, or $1.23 per diluted common share, surpassing Wall Street expectations of $1.84 per share on $6.11 billion in revenue. Revenues increased 5.5% year-over-year to $6.3 billion, with non-GAAP core revenue growing 3.0%. The company raised its full year 2026 adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60, compared to previous guidance of $8.35 to $8.55, citing strong earnings performance and the earlier-than-anticipated completion of the Masimo acquisition.
Rainer M. Blair, President and Chief Executive Officer, attributed the better-than-expected results to disciplined execution driving high-single-digits adjusted EPS growth and the Life Sciences businesses delivering their strongest quarter in several years. Bioprocessing orders grew mid-teens in the quarter, though customer project timing impacted revenue. Looking ahead, the company expects to exit 2026 at a mid-single-digit core revenue growth rate.
Financial Performance
Operating cash flow for the quarter was $1.5 billion, and non-GAAP free cash flow was $1.3 billion. Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94. The company anticipates third quarter 2026 non-GAAP core revenue will increase in the 2.0% to 3.0% range year-over-year.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net Earnings | $870 million | $555 million | 60% ↑ |
| Diluted EPS | $1.23 | $0.77 | 60% ↑ |
| Revenues | $6.3 billion | $5.9 billion | 5.5% ↑ |
| Operating Cash Flow | $1.5 billion | $1.3 billion | — |
| Non-GAAP Free Cash Flow | $1.3 billion | $1.1 billion | — |
Segment Performance
Total sales growth was 5.5% for the quarter. Core sales growth (non-GAAP) was 3.0%, while core sales growth excluding respiratory testing was 4.5%. The Life Sciences segment led performance with 5.5% core sales growth, followed by Biotechnology at 2.5% and Diagnostics at 2.0%.
Outlook
For the full year 2026, Danaher expects non-GAAP core revenue to increase in the 3.0% to 4.0% range. The company also announced its intention to acquire StatLab, a manufacturer of histology workflow products, which generated approximately $250 million in revenue for the full year 2025. The acquisition is expected to close by the end of 2026.
How will the earlier-than-anticipated completion of the Masimo acquisition impact Danaher's integration costs and synergies for the remainder of 2026?
What specific factors are driving the mid-teens growth in Bioprocessing orders, and when will these translate into revenue recognition?
How does the planned acquisition of StatLab align with Danaher's long-term strategy in the Diagnostics segment?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
